Kymbee Suspension
NDC Package 0245-0813-13

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Kymbee (deflazacort) suspension is classified as a

administered via oral route. This formulation utilizes a suspension delivery system. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 0245-0813 and is authorized under FDA application ANDA216992.

Identification & Billing

NDC Package Code
0245-0813-13
Package Description
1 BOTTLE in 1 CARTON / 13 mL in 1 BOTTLE
Product Code
0245-0813
11-Digit Billing Format
00245081313

Clinical Specifications

Proprietary Name
Kymbee
Non-Proprietary Name
Deflazacort
Substance Name
Deflazacort
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DEFLAZACORT 22.75 mg/mL
Pharmacologic Class

Regulatory & Marketing

Labeler Name
Upsher-smith Laboratories, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA216992
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-05-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0245-0813-13 identifies a specific commercial package of 1 bottle in 1 carton / 13 ml in 1 bottle of Kymbee, a human prescription drug labeled by Upsher-smith Laboratories, Llc. This suspension is formulated for oral use and contains deflazacort as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Llc on June 05, 2026. The current certification is valid through December 31, 2027.

How is this Upsher-smith Laboratories, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00245081313. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0245-0813-13
11-Digit CMS (5-4-2)
00245-0813-13

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.